Insilico's Chemistry42 AI system integrated into UCB's drug discovery programs

Rhea-AI Summary

Insilico Medicine announced the integration of its Chemistry42™ platform into UCB's drug discovery pipeline, enhancing UCB's ability to design new hit compounds efficiently. This collaboration aims to reduce costs and streamline the drug development process. Chemistry42™ will be customized for UCB's cloud-based supercomputing infrastructure, enabling rapid, user-defined druglike properties formulation. UCB's commitment to AI-powered drug discovery further solidifies its leadership in the biopharmaceutical sector.

Positive

• Integration of Insilico's Chemistry42™ platform expected to decrease costs and improve efficiency in drug development.
• Collaboration highlights UCB's commitment to innovative drug discovery through AI technology.

Negative

• None.

HONG KONG, March 9, 2021 /PRNewswire/ -- Insilico Medicine, an AI drug discovery company, announced that UCB will integrate Insilico's Chemistry42™ into UCB's internal drug discovery pipeline. UCB's early adoption of Insilico Medicine's proprietary technology will provide UCB's scientists with the ability to design novel hit compounds that satisfy multiple predefined parameters rapidly and streamline lead optimization. With the Chemistry42™ platform, UCB scientists will also reduce the efforts and costs typically associated with the design, testing and commercialization of new drugs. Chemistry42™ v1.0 will be customized and deployed on UCB's cloud-based supercomputing infrastructure.

Chemistry42™ is a flexible, user-friendly software platform that integrates artificial intelligence (AI) methods with the fields of medicinal and computational chemistry for the design of novel small molecules with user-defined druglike physicochemical properties. The platform is a scalable distributed web application capable of running multiple tasks in parallel in a matter of hours. Container orchestration and workflow management allow for predictable hardware-agnostic resource allocation and the implementation on either cloud or local HPC infrastructures.

"UCB is one of the leading companies in small molecule drug discovery. It was their insight and approach at the forefront of this science that encouraged us to move into AI-powered chemistry over five years ago and it gives me great pleasure to see UCB among the launch partners of our Chemistry42 operating system," said Alex Zhavoronkov, Ph.D., CEO of Insilico Medicine.

"Insilico Medicine has been very responsive in this quickly developing area of science and we are delighted to be one of the launch partners for Chemistry42," Jiye Shi, Global Head of Computer-Aided Drug Design at UCB said. "Our hope is that this platform will further enhance the digital transformation of our drug discovery capabilities for the benefit of patients worldwide."

About Insilico Medicine

Insilico Medicine develops software that leverages generative models, reinforcement learning (RL), and other modern machine learning techniques to generate new molecular structures with specific properties. Insilico Medicine also develops software for the generation of synthetic biological data, target identification, and the prediction of clinical trial outcomes. The company integrates two business models: providing AI-powered drug discovery services and software through its Pharma.AI platform (www.insilico.com/platform/) and developing its pipeline of preclinical programs. The preclinical program is the result of pursuing novel drug targets and novel molecules discovered through its platforms. Since its inception in 2014, Insilico Medicine has raised over $52 million and received multiple industry awards. Insilico Medicine has also published over 100 peer-reviewed papers and has applied for over 25 patents.

Website https://insilico.com/

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With 7,500 people in approximately 40 countries, the company generated revenue of € 4.9 billion in 2019. UCB is listed on Euronext Brussels (symbol: UCB).

Media Contact
For further information, images, or interviews, please contact polly.firs@insilico.com.

UCB Media Contact
Karen Borrer
+44 (0)1753 713006
Karen.borrer@ucb.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/insilicos-chemistry42-ai-system-integrated-into-ucbs-drug-discovery-programs-301243305.html

SOURCE Insilico Medicine

FAQ

What is the significance of UCB integrating Chemistry42™ from Insilico Medicine?

The integration of Chemistry42™ enhances UCB's drug discovery pipeline, allowing for more efficient and cost-effective design of new drug compounds.

How will Chemistry42™ affect UCB's drug development process?

Chemistry42™ is expected to streamline lead optimization and reduce the time and costs associated with developing new drugs.

When was the announcement made regarding UCB and Insilico Medicine's collaboration?

The announcement was made on March 9, 2021.

What benefits does Insilico's Chemistry42™ offer to UCB?

It allows UCB's scientists to quickly design novel hit compounds that meet specific parameters, enhancing their drug discovery capabilities.

What are UCB's current business focuses?

UCB focuses on the discovery and development of innovative medicines for severe diseases affecting the immune system and central nervous system.